CAS: 147228-37-3; (R)-3-Amino-5-Phenylpentanoic Acid

该化合物是一种乳性β-氨酸衍生物,在β位置上具有同苯基替代成分,该化合物因其立体化学纯度和多功能反应性,在非对称合成和药物研究中具有价值.该化合物的配置确保了高对等选择性,使之适合用于恋童癖,催化剂设计和生物活性分子开发.其僵硬结构和功能组兼容性允许精确地修改药物发现和物质科学.同苯基集团加强了脂性,提高了治疗剂的薄膜渗透性.该化合物通常供应高化学纯度,确保合成和药用化学应用的可靠性.

结构式图片

相似化合物

218608-84-5 269398-87-0 218278-62-7

欧盟法规

C&L通报

上下游产品

3-hydroxyamino-5-phenylpentanoic acid 3-phenyl-propionaldehyde malonic acid 5-phenyl-2(E)-pentenoic acid 3-(R)-[(1-cyano-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]-5-phenylpentanoic acid

合成工艺路线路线简述

    (3R)-5-Phenyl-3-(Tosylamino)Pentanoic Acid置于氢溴酸,Methyloxirane体系中,化学反应生成D-3-氨基-5-苯基戊酸.盐酸盐
    参考文献:β-氨基酸,它们的α-羟基衍生物以及bestatin和microginin的n端组分的对映选择性合成
    标题:β-氨基酸,它们的α-羟基衍生物以及bestatin和microginin的n端组分的对映选择性合成
    摘要:通过甲苯磺酸化,酸酐形成和用nabh 4还原而得到的l-天冬氨酸被转化为(3S)-3-(甲苯磺酰基氨基)丁烷-4-醇化物(8;方案1).的tretment 8用乙醇三甲基碘硅烷,得到ñ-保护的脱氧碘β-高丝氨酸乙酯9.后者在连续的亲核置换过程中,用二烷基铜锂(10A-E),碱性水解(11A-E)和甲苯磺酰基的还原去除,产生了相应的4-取代的(3 R)-3-氨基丁酸12A.-E(ee> 99%).8的亲电羟基化(19;方案3),随后的碘酯化(21;方案4),以及在皂化和脱保护后,进行亲核烷基化和苯基化,得到一系列的4-取代的(2 S,3 R)-3-氨基-2-羟基丁酸24分别包括bestatin和microginin(de> 95%)的n端酸24E(= 3)和24F(= 4).
    Doi:10.1002/hlca.19960790426

    海关参考信息

    专利信息


    专利号:US-2022243244-A1
    优先权日:2019-10-10
    标 题 :Compositions and methods for in vivo synthesis of unnatural polypeptides
    发明人:ROMESBERG FLOYD E; FISCHER EMIL C; HASHIMOTO KOJI; FELDMAN AARON W; DIEN VIVIAN T; ZHANG YORKE
    权利人:SCRIPPS RESEARCH INST
    摘要:Disclosed herein are compositions, methods, and kits for a cell incorporating unnatural amino acids into an unnatural polypeptide. Also disclosed herein are compositions, methods, and kits for increasing activity and yield of the unnatural polypeptide synthesized by the cell.

    专利号:US-2025084410-A1
    优先权日:2015-01-12
    标 题:Incorporation of unnatural nucleotides and methods thereof
    发明人:PTACIN JEROD; MALYSHEV DENIS A; CAFFARO CAROLINA E
    权利人:SYNTHORX INC
    摘要:Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.

    专利号:US-2018371021-A1
    优先权日:2017-05-11
    标 题 :Peptidomimetic macrocycles and uses thereof
    发明人:AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN
    权利人:AILERON THERAPEUTICS INC
    摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.

    专利号:US-2005009151-A1
    优先权日:2003-07-10
    标 题 :Methods for the stereospecific and enantiomeric enrichment of beta-amino acids
    发明人:CHASE MATTHEW; CLAYTON ROBERT; LANDIS BRYAN; BANERJEE AMIT
    权利人:PHARMACIA CORP
    摘要:The present invention relates to methods for the stereospecific synthesis and for the enantiomeric enrichment of β-amino acids. A novel D-β-aminotransferase, which exhibits stereoselectivity for D-β-phenylalanine, (D-3 amino-3-phenylpropinine acid) was purified from a newly-isolated strain of Variouorax paradoxus . A novel L-β-aminotransferase was purified from a newly-isolated strain of Alcaligenes eutrophus . The D- and L-β-aminotransferases can be used to facilitate the stereoselective biosynthesis of β-D-phenylalanine or β-L-phenylalanine, from a mixture of L-glutamic acid or L-alanine, respectively, and 3-keto-3-phenylpropionic acid in the presence of the cofactor pyridoxal phosphate.

    专利号:WO-2021072167-A1
    优先权日:2019-10-10
    标 题:Compositions and methods for in vivo synthesis of unnatural polypeptides

    专利号:US-11091522-B2
    优先权日:2018-07-23
    标题 :Peptidomimetic macrocycles and uses thereof
    发明人:AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN; ANNIS DAVID ALLEN
    权利人:AILERON THERAPEUTICS INC
    摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
    上海恒创生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hcbiotech.com.cn
    电话: 021-20227858👤
    📞上海恒创生物科技有限公司 ⚠️参考联系方式

    销售电话:021-20227858
    邮箱:sale@hcbiotech.com.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知